Key Developments and Trends Steering the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forward: Glaxosmithkline Introduces Trelegy Ellipta A Revolutionary Single-Inhaler Triple Treatment For Chronic Obstructive Pulmonary Disease (COPD)
Discover trends, market shifts, and competitive outlooks for the chronic obstructive pulmonary disease (copd) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Performance Trended Historically, And What Lies Ahead?
The market for treatment of chronic obstructive pulmonary disease (COPD) has been on a robust growth trajectory in recent years. From a size of $20.84 billion in 2024, it is set to expand to $21.94 billion in 2025, yielding a compound annual growth rate (CAGR) of about 5.3%. Factors contributing to this growth during the historical period include a widespread smoking epidemic and usage of tobacco, advancements in inhalation therapies, consciousness programs and early detection techniques, government efforts aimed at respiratory health, and extensive research and development in the field of pulmonology.
The market size for treatment of chronic obstructive pulmonary disease (COPD) is projected to experience robust expansion in the coming years. The expected growth is to reach $27.74 billion by 2029, with a compound annual growth rate (CAGR) of 6.0%. The anticipated growth during the forecast period is due predominantly to personalized medicine and biomarker research, biologic treatments and specific interventions, concerns over air quality and environmental influences, worldwide initiatives for smoking cessation, and partnerships for drug development. Key trends projected in the forecast period encompass digital health solutions for handling COPD, novel biologic treatments for COPD, the development of personalized medicine, combined therapies and inhalers, and early diagnostic and intervention procedures along with pulmonary rehabilitation programs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theChronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The rise in instances of lung disease is predicted to drive the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung ailments impede the normal functioning of the lungs, with the most common comprising asthma, COPD, and lung cancer. Chronic obstructive pulmonary disease (COPD) treatments are primarily employed to manage lung disorders, slow down the progress of the ailment, control the symptoms, and prevent lung damage with the use of inhalers and medication. For example, as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a non-profit organization based in the US, COPD kills approximately 3.2 million individuals annually and impacts an expected 200 million people. Additionally, the global population of asthma sufferers reached 262 million in 2022. These figures are anticipated to grow. Additionally, according to the LUNGevity Foundation in 2023, a further American non-profit organization, lung cancer will result in the demise of 127,000 Americans annually. As a result, the escalating occurrence of lung diseases is fueling the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
Which Segments in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Offer the Most Growth?
The chronic obstructive pulmonary disease (COPD) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theChronic Obstructive Pulmonary Disease (COPD) Treatment Market?# Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Current Market Growth and Trends in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry?
The growing trend of product innovation is becoming increasingly important in the chronic obstructive pulmonary disease (COPD) treatment market. Big-name businesses in the market for chronic obstructive pulmonary disease (COPD) treatment are shifting their focus to the creation of cutting-edge products to stay relevant in the marketplace. For example, in April 2022, Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) was introduced in India as the first single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary disease (COPD) by GlaxoSmithKline plc (GSK), a pharmaceutical and biotech company based in the UK. Trelegy Ellipta, used as a maintenance drug for people aged 18 and older to treat and prevent the symptoms of COPD, operates similarly to natural corticosteroid hormones by binding to receptors on specific immune cell types, thereby reducing immune system activity. It also aids in reducing lung airway inflammation, making breathing easier.
View the full report here:
What Are the Key Elements That Define the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Chronic obstructive pulmonary disease (COPD) treatment refers to medical care given to a patient that helps manage the symptoms, slow the progression, and improve the overall quality of life of individuals with COPD. COPD is a progressive respiratory disease characterized by airflow obstruction, chronic inflammation, and damage to the lung tissue.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10054
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
